| Not Yet Recruiting | A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine NCT07256912 | International Agency for Research on Cancer | Phase 4 |
| Not Yet Recruiting | Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema NCT07429474 | Laboratorios Sophia S.A de C.V. | Phase 1 |
| Recruiting | Influenza Vaccination Strategy for Patients With Hematologic Malignancy NCT07485855 | Asan Medical Center | Phase 3 |
| Active Not Recruiting | Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC NCT06844500 | Jean-Pierre Van geertruyden | Phase 3 |
| Recruiting | Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC NCT06844487 | Jean-Pierre Van geertruyden | Phase 3 |
| Unknown | A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2 NCT05911087 | Stemirna Therapeutics | Phase 2 / Phase 3 |
| Active Not Recruiting | Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocyt NCT06497036 | Geropharm | Phase 3 |
| Unknown | mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs NCT05686161 | Stemirna Therapeutics | Phase 3 |
| Unknown | New Generation mRNA Booster Vaccine Against Emerging VOCs NCT05580159 | Stemirna Therapeutics | Phase 3 |
| Completed | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults NCT05383560 | Sheba Medical Center | Phase 2 |
| Completed | Immunogenicity of COVID-19 Vaccine on Heterologous Schedule NCT05054621 | Chang Gung Memorial Hospital | Phase 2 |
| Unknown | Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study NCT05115617 | Ottawa Hospital Research Institute | — |
| Unknown | Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies NCT04878822 | Ospedale di Circolo - Fondazione Macchi | — |
| Completed | Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial NCT04961385 | Bangkok Metropolitan Administration Medical College and Vajira Hospital | — |
| Unknown | Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines NCT05150834 | Korea University Guro Hospital | — |
| Completed | COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS NCT04754698 | University of Sao Paulo General Hospital | Phase 4 |
| Completed | Bioequivalence Clinical Trial of Recombinant Human Follicle-stimulating Hormone JZB30 NCT06778304 | West China Second University Hospital | Phase 1 |
| Completed | Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombina NCT04071379 | PT Bio Farma | Phase 3 |
| Completed | Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III) NCT04051268 | PT Bio Farma | Phase 3 |
| Completed | Protectivity and Safety Following Recombinant Hepatitis B Vaccine NCT03919578 | PT Bio Farma | Phase 2 / Phase 3 |
| Completed | EMaBS TB Vaccine Study NCT03681860 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and I NCT03460405 | PT Bio Farma | Phase 2 |
| Completed | Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharma NCT04015232 | Intas Pharmaceuticals, Ltd. | Phase 1 |
| Completed | Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and NCT03680417 | PT Bio Farma | Phase 4 |
| Completed | Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa NCT03722615 | University of Witwatersrand, South Africa | — |
| Completed | A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With o NCT01697007 | Muhimbili University of Health and Allied Sciences | Phase 2 |
| Unknown | Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants NCT01763268 | Queen Sirikit National Institute of Child Health | Phase 2 / Phase 3 |
| Completed | A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants NCT01399853 | Jiangsu Province Centers for Disease Control and Prevention | Phase 2 |
| Completed | Shigella Sonnel O-SPC/rBRU Conjugate Vaccine NCT01369927 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |
| Completed | Gardasil Vaccination in Post Stem Cell Transplant Patients NCT01092195 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 |